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Abstract
A press conference on Thursday September 24 in Bangkok, Thailand, released data that an
experimental vaccine provided mild protection against HIV-1 infection. This is the first positive
signal of any degree of vaccine efficacy in humans, more than a quarter-century after scientists
discovered the virus that causes AIDS. The research was conducted by a team including Thai
researchers, the U.S. Army and the U.S. National Institutes of Health. The RV144 Phase III clinical
trial, which began in 2003, had been disparaged by many critics as a waste of time and money
because each of the two components had been shown to produce no benefit as individual vaccines
and because the scientific rationales behind the immunogens were just wrong. It was nevertheless
speculated that using them together in the prime-boost scenario could be more effective, with the
aim to induce heightened CD4+ cellular immune responses against the viral Envelope protein. This
optimism seems to have been validated. In fact, this would not be the first time that the discovery
of an effective vaccine relied as much on serendipity as opposed to scientific rationale. On the other
hand, many questions remain about the RV144 trial, and these issues will be addressed in this
editorial.
The press conference
The limited information provided by the trial sponsors in
their press release is that 74 out of 8,198 volunteers who
received placebo immunizations became infected with
HIV-1 compared to 51 out of 8,917 volunteers who
received the prime-boost vaccine. The results equate to a
protective efficacy of a little over 31%, with a p value of
less than 0.039, just below the widely accepted signifi-
cance cutoff of 0.05. The vaccine had no effect on post-
infection viral loads among the recipients who became
infected.
This 31% value is below the 50% reduction rate defined
as "unequivocal clinical benefit", and the margin of error
is wide; so it does not suggest that the experimental vac-
cine should now be deployed for general use. On the
other hand, it is enough to justify further research into
deciphering the underlying mechanism which provides
for the protection observed and - when the results will be
sustained during the coming months - putting additional
efforts into improving this approach.
The vaccine components
The priming vaccine, called ALVAC and made by Sanofi
Pasteur in Lyon, France, consists of a version of the
canarypox viral vector that was engineered to contain syn-
thetic versions of three HIV-1 genes that encode the Gag
and Protease proteins of subtype B and a chimeric form of
the Envelope protein (subtype E gp120 linked to a portion
of the subtype B gp41 domain). This type of viral expres-
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was tested by Merck in the STEP trial that failed to show
protection [1]. Further study of the STEP results found a
potentially increased risk of HIV-1 infection among vacci-
nated men who had high levels of pre-existing immunity
against the vector. These viral vector based vaccines are
designed to stimulate human immune cells to fight HIV-
1.
The boosting antigen in AIDSVAX is a genetically engi-
neered version of the gp120 Envelope protein, originally
designed by the California biotech firm VaxGen. This
bivalent vaccine contains equal concentrations of the sub-
type B and E gp120 antigen. Its purpose is to stimulate the
production of antibodies that can neutralize HIV-1.
The antigens used in the vaccine come from the subtypes
which are the most common forms in, respectively, North
America and Europe, and in South-East Asia. Thus, there
is a perfect match between this vaccine and the test loca-
tion in Thailand. Both ALVAC and AIDSVAX vaccines con-
sist of only pieces of HIV-1, not the whole virus, and
therefore cannot cause AIDS and both are intended for
those uninfected with HIV-1, to educate their immune
systems to be able to fight off HIV-1 infection should they
later be exposed to the virus.
The priming component of the RV144 trial, ALVAC, had
been tested for safety in previous trials, but none of those
trials was designed to see if it was efficacious [2]. The
boosting component, AIDSVAX, had been the subject of a
previous trial in Thailand, and also one in North America
and Europe. Those two trials, intended to raise a tradi-
tional antibody-based response, were regarded at the time
as the best hope for an effective vaccine, although they
also met with critiques up front from the scientific com-
munity because the Envelope protein used adopts a con-
formation that raises predominantly the wrong, non-
neutralizing antibodies. The trials were a bitter disap-
pointment, showing no effect whatsoever, although AID-
SVAX was shown to be safe [3].
The specifics of the RV144 trial
A full vaccination course of the RV144 regime lasts six
months and consists of four ALVAC shots and two AIDS-
VAX shots, with a 50% chance of this being a placebo
rather than the vaccine. The adult volunteers between ages
18 and 30 were drawn from the general public, rather than
specifically from groups at risk such as men having sex
with men (MSM), recreational drug injectors, or commer-
cial sex workers (CSW). This may explain in part the low
number of persons that acquired HIV-1 during the 6 year
follow-up. In fact, only 125 of the 17,115 participants
became infected during the trial, which is in all likelihood
due to effective HIV-1 prevention counseling and condom
distribution. Indeed, this may turn out to be the biggest
success story of this trial. With such low numbers, it
would have been important to obtain another independ-
ent measure of vaccine efficacy. Vaccines that provide pro-
tection against virus infection usually also have an impact
on the amount of virus that can be measured in the indi-
viduals that failed to be protected. Vaccine studies in the
SIV-macaque model have also indicated that it is easier to
obtain a therapeutic effect (reduction of viral load in
established infection) than a truly prophylactic effect
(protection against a new infection). Possibly the most
surprising result of the RV144 study is that the vaccine
appeared to provide mild protection while having no
effect on the viral load in those who became infected.
Such a scenario points to good induced mucosal
responses that do not translate to control of viral replica-
tion following HIV-1 infection. This result, which pro-
vides for much of the excitement to the study, remains a
big puzzle that should be addressed in follow-up experi-
ments. However, for the moment an independent meas-
ure of vaccine efficacy is lacking.
The restrained enthusiasm seems appropriate in the
absence of more detailed information on the study
results. In particular, based on the limited amount of
information provided, the statistical significance hangs on
a very few cases of HIV-1 infection. For instance, the
results could be skewed by subtle differences between the
vaccine and control groups, in particular because the over-
all percentage of HIV-1 infection is relatively low in this
study group. Because of the small numbers, the accidental
overrepresentation of some individuals engaged in high-
risk sexual activity or condom usage could have a big
effect on the statistical significance reached. The RV144
study did not exclude high-risk people, and at baseline
about one-fourth reported having high-risk behavior such
as MSM or CSW. Male circumcision is also a factor associ-
ated with risk of HIV-1 transmission, and obviously the
overrepresentation of circumcised or non-circumcised
men in the two groups could confer some bias. Interest-
ingly, male circumcision has proved to have a higher pro-
tection rate against HIV-1 transmission than reported with
this vaccine. It is expected that more data will be presented
at the annual AIDS Vaccine Conference in Paris (October
19-22, 2009), but how much information will be released
remains to be seen.
How to proceed
The trial has certainly posed more new questions than it
has so far answered. Some of these issues can be addressed
in follow-up analysis of the materials collected during the
trial, but new clinical trials would seem required to
address other issues. First of all, it would seem importantPage 2 of 3
(page number not for citation purposes)
Retrovirology 2009, 6:88 http://www.retrovirology.com/content/6/1/88to arrange an extended follow-up of the RV144 trial, if
possible, to increase the numbers and to test for durable
vaccine effects.
Follow-up laboratory work can address several issues. The
key issue is to identify the correlates of protection. In
other words, what mechanism or molecule correlates with
the observed protection, and can this also explain why no
effect is seen on the viral load in those individuals that
became infected despite receiving the vaccine? This
reminds us of the early progress on live-attenuated SIV
variants in the macaque model, where good protection
was obtained [4]. However, the correlates of protection
were never clearly defined, and this track has lost momen-
tum because these replicating vaccine viruses turned out
not to be safe [5]. Another relevant issue is to dissect
whether the observed protection shows specificity for the
B or E subtype, which is possible because the ALVAC com-
ponent does not have an identical B/E composition. In
fact, such a difference may improve the statistical rele-
vance of the study. Likewise, ethnic differences may also
be relevant to consider [6]. Additionally, viral sequencing
and comparison between infected vaccine and placebo
recipients may provide insights into whether Envelope
sequences have been selected to escape from vaccine pres-
sure.
A major issue is that, in the absence of efficacy data on
ALVAC as an individual vaccine, it will be difficult to dis-
sect whether inclusion of AIDSVAX yielded any benefit.
Possibly laboratory analysis can help to provide an
answer, but otherwise new human trials will be required
to address this issue. New trials would also seem required
to determine whether similar results can be obtained in
high-risk populations such as MSM, injecting drug users,
and high-risk heterosexuals such as CSW.
It will require hard work to translate this landmark result
into a true public health benefit. One criticism of the
RV144 study design is that it does not match the situation
in sub-Saharan Africa where two-thirds of the world's
HIV-infected people live, and two-thirds of all new infec-
tions are happening. This continent, where HIV-1 origi-
nated from multiple zoonotic transfers from primates, has
the greatest variety of HIV-1 subtypes, but subtypes B and
E are not common there. However, it seems relatively
straightforward to modify the RV144 components to
match the subtypes that are more relevant at the global
level, such as subtype A and C.
The results of the RV144 trial may indicate that we should
not put all our money on basic science and ignore clinical
science, as human experimentation has added value over
what we can test in tubes and animal models. However, it
seems critical to maintain the appropriate balance
between basic vaccinology science and empirical clinical
trials. At the same time, we should not make the mistake
of focusing future vaccinology research exclusively on the
components of the RV144 vaccine and thereby hamper
the development of other innovative approaches. This
seems particularly important because nobody can predict
which vaccine direction will lead to an effective and safe
vaccine that protects against infection. One lesson learned
is not to throw away old vaccines too quickly, but this
should not jeopardize the research pipeline towards novel
vaccine approaches. Such alternative strategies range from
the molecular manipulation of the viral Envelope protein
to become a better immunogen [7-9], to the presentation
of early HIV-1 regulatory proteins to the immune system
[10], to gene therapy approaches to express antibody-like
molecules [11], to the generation of safer versions of live-
attenuated virus vaccine candidates [12].
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